Altered cleavage of human factor VIII at the B-domain and acidic region 3 interface enhances expression after gene therapy in hemophilia A mice

Background: Variants of human factor VIII (hFVIII) have been developed to further understand the structure and function of hFVIII and improve gene-based therapeutics. We have previously characterized several hFVIII variants of the furin cleavage site (1645-1648) with improved secretion. We have also identified a second cleavage site in the acidic region 3 (a3) (1657-1658) that becomes the primary hFVIII intracellular cleavage position in the absence of the furin site. We tested a hypothesis that modification of this site may confer additional functional advantages to hFVIII.Objectives: The aim of this study was to conduct the biochemical and functional characterization of hFVIII variants of the furin cleavage site, the a3 cleavage site, or in combination, both in vitro and in vivo after AAV mediated gene therapy. Methods: Recombinant hFVIII variants of the furin cleavage site (hFVIII-A3), the a3 cleavage site (hFVIII-S1657P/D1658E [SP/DE]), or in combination (hFVIII-A3-SP/DE) were purified and characterized in vitro and in vivo.Results: Recombinant hFVIII-A3, hFVIII-SP/DE, and hFVIII-A3-SP/DE variants all had comparable specific activity to B-domain deleted (BDD) hFVIII. Hemophilia A mice tolerant to hFVIII did not develop immune responses to hFVIII after protein challenge with these variants or after adeno-associated virus (AAV) delivery. Following AAV delivery, hFVIII-A3-SP/DE resulted in expression levels that were 2- to 5-fold higher than those with hFVIII-BDD in hemophilia A mice. Conclusion: The novel hFVIII-A3-SP/DE variant of the furin and a3 cleavage sites significantly improved secretion compared with hFVIII-BDD. This key feature of the A3-SP/DE variant provides a unique strategy that can be combined with other ap proaches to further improve factor VIII expression to achieve superior efficacy in AAV-based gene therapy for hemophilia A.

Automated summary

This study investigates the biochemical and functional characteristics of various variants of human factor VIII (hFVIII) in vitro and in vivo after gene therapy using adeno-associated virus (AAV). The results demonstrate that the furin cleavage site and the a3 cleavage site variants significantly improve hFVIII secretion and have comparable specific activity to the existing variants, without inducing immune responses.